1-Brom-4-butyloxy-2,6-dimethyl-benzol | 91560-97-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-Brom-4-butyloxy-2,6-dimethyl-benzol
• 英文别名: (4-bromo-3,5-dimethyl-phenyl)-butyl ether；(4-Brom-3,5-dimethyl-phenyl)-butyl-aether；1-bromo-4-butoxy-2,6-dimethylbenzene；2-Bromo-5-butoxy-1,3-dimethylbenzene
• CAS: 91560-97-3
• 化学式: C₁₂H₁₇BrO
• 分子量: 257.17
• InChiKey: TZILHQINDNOUDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  正溴丁烷 、 4-溴-3,5-二甲酚 在 氢氧化钾 作用下， 生成 1-Brom-4-butyloxy-2,6-dimethyl-benzol
  参考文献：
  名称：

  Honkanen, Acta Chemica Scandinavica (1947), 1959, vol. 13, p. 1189,1190

  摘要：

  DOI：

文献信息

• [EN] ANTIDIABETIC TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015051725A1

  公开（公告）日：2015-04-16

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能在治疗、预防和抑制由G蛋白偶联受体40介导的疾病方面有用。本发明的化合物可能在治疗2型糖尿病以及通常与该疾病相关的疾病，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症方面有用。
• New pharmaceutical combinations for NOS inhibitors
  申请人：Pfizer Inc

  公开号：US20040229911A1

  公开（公告）日：2004-11-18

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂活性的化合物的新药物用途。具体地，涉及使用NOS抑制剂，特别是选择性神经元NOS（nNOS）抑制剂，单独或与另一种活性剂联合使用，特别是SSRI或NK-1受体拮抗剂，用于治疗可以通过改变昼夜节律来达到或促进治疗的疾病或病况。这些疾病和病况的例子包括失明、肥胖症、季节性情感障碍、双相情感障碍、时差反应、昼夜节律睡眠障碍、睡眠剥夺、睡眠障碍、REM睡眠障碍、嗜睡症、睡眠-觉醒周期障碍、嗜睡症和与轮班工作或不规则工作时间表相关的睡眠障碍、夜尿症和不宁腿综合症。
• ANTIDIABETIC TRICYCLIC COMPOUNDS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2880028B1

  公开（公告）日：2020-09-30
• [EN] BI-ARYL COMPOUND HAVING IMMUNOSUPPRESSIVE ACTIVITY<br/>[FR] COMPOSE BI-ARYLE PRESENTANT UNE ACTIVITE IMMUNOSUPPRESSIVE
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2005014525A2

  公开（公告）日：2005-02-17

  The invention is directed to a bi-aryl compound having a unique immunomodulating activity, a process for a preparation thereof, a pharmaceutical composition containing the same, and a method of preventing or treating disorders or diseases mediated by T lymphocytes by administering the compound to a subject in need of treatment.
• Honkanen, Acta Chemica Scandinavica (1947), 1959, vol. 13, p. 1189,1190
  作者：Honkanen

  DOI：——

  日期：——